David H. Gultekin1,2, William R. Jarnagin3, Jason A. Koutcher1, Mithat Gonen4, Dana Haviland3, Leslie H. Blumgart3, Michael I. D'Angelica3, Yuman Fong3, Ronald P. DeMatteo3, Nancy E. Kemeny5, Lawrence H. Schwartz2
1Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 3Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 5Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
The role of DCE-MRI has been evaluated in a Phase II clinical study for the assessment of response to therapy in patients with unresectable primary liver cancers, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), undergoing regional chemotherapy through continuous hepatic arterial infusion (HAI) treatment procedure.